Scholarlink

Background <p>Early tumor shrinkage (ETS) and depth of response (DpR) are early indicators of survival in patients with metastatic colorectal cancer (mCRC) undergoing anti-epidermal growth factor receptor monoclonal antibody treatment. However, their relevance in v-raf murine sarcoma viral oncogene homolog B1 (<i>BRAF</i>) V600E mutant (MT) mCRC remains unclear. In this study, we evaluate the association between ETS/DpR and clinical outcomes in <i>BRAF</i> V600E MT mCRC.</p> Patients and methods <p>Patients with mCRC who were diagnosed with <i>BRAF</i> V600E MT and treated with first-line chemotherapy between June 2011 and March 2023 at a single cancer institute were enrolled. The association between ETS/DpR and clinical outcomes in patients with at least one target lesion was assessed. The cutoff value for ETS and DpR was set at 20% and 25%. Multivariate analysis of factors affecting progression-free survival (PFS) and overall survival (OS) was conducted.</p> Results <p>In total, 54 patients with <i>BRAF</i> V600E MT mCRC exhibited at least one target lesion. Patients with ETS and DpR were 24 (44.4%) and 27 (50%), respectively. Moreover, median PFS and OS were 7.5 and 17.1&#xa0;months, respectively. Patients with ETS exhibited longer PFS and tended toward longer OS than those without ETS. Similarly, patients with DpR exhibited longer PFS and OS than those without DpR. Multivariate analysis confirmed a significant association between DpR and longer PFS and OS.</p> Conclusion <p>ETS and DpR could serve as early surrogate markers of clinical outcomes in patients with <i>BRAF</i> V600E MT mCRC treated with first-line chemotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer

  • 期刊论文

  • 发表日期：

    2025年2月27日

查看全文
  • Shohei Udagawa,
  • Hiroki Osumi,
  • Akira Ooki,
  • Keitaro Shimozaki,
  • Takeru Wakatsuki,
  • Shota Fukuoka,
  • Koichiro Yoshino,
  • Mikako Tamba,
  • Mariko Ogura,
  • Keisho Chin,
  • Kensei Yamaguchi,
  • Eiji Shinozaki

摘要

Background

Early tumor shrinkage (ETS) and depth of response (DpR) are early indicators of survival in patients with metastatic colorectal cancer (mCRC) undergoing anti-epidermal growth factor receptor monoclonal antibody treatment. However, their relevance in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutant (MT) mCRC remains unclear. In this study, we evaluate the association between ETS/DpR and clinical outcomes in BRAF V600E MT mCRC.

Patients and methods

Patients with mCRC who were diagnosed with BRAF V600E MT and treated with first-line chemotherapy between June 2011 and March 2023 at a single cancer institute were enrolled. The association between ETS/DpR and clinical outcomes in patients with at least one target lesion was assessed. The cutoff value for ETS and DpR was set at 20% and 25%. Multivariate analysis of factors affecting progression-free survival (PFS) and overall survival (OS) was conducted.

Results

In total, 54 patients with BRAF V600E MT mCRC exhibited at least one target lesion. Patients with ETS and DpR were 24 (44.4%) and 27 (50%), respectively. Moreover, median PFS and OS were 7.5 and 17.1 months, respectively. Patients with ETS exhibited longer PFS and tended toward longer OS than those without ETS. Similarly, patients with DpR exhibited longer PFS and OS than those without DpR. Multivariate analysis confirmed a significant association between DpR and longer PFS and OS.

Conclusion

ETS and DpR could serve as early surrogate markers of clinical outcomes in patients with BRAF V600E MT mCRC treated with first-line chemotherapy.